ClinicalTrials.Veeva

Menu

Efficacy of the Quell Wearable Device for Chronic Low Back Pain

Mass General Brigham logo

Mass General Brigham

Status

Completed

Conditions

Low Back Pain

Treatments

Device: Quell

Study type

Interventional

Funder types

Other

Identifiers

NCT02944513
2016P002172

Details and patient eligibility

About

This is a 1-year trial designed to gather information about the use of the Quell for persons with chronic musculoskeletal low back pain.

Full description

Research Objectives: This is a 1-year trial designed to gather information about the use of the Quell for persons with chronic musculoskeletal low back pain. The investigators hypothesize that those assigned to using the device will report reduced back pain compared with those in the control condition; with those using the device also showing improvement in sleep, mood, and level of activity. The investigators hypothesize that frequency of using the Quell (increased tolerability and adherence) will be correlated with greater reduction in pain. The investigators hypothesize that the device will be safe to use and will demonstrate a reduction in healthcare utilization (reduced clinic and Emergency Department visits). Finally, based on preliminary analyses limited by few subject numbers, the investigators will investigate whether certain individuals report greater benefit from using the Quell than others and, in particular, would predict that those with more intense and longer duration of pain will demonstrate most benefit.

Enrollment

68 patients

Sex

All

Ages

21 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All participants will be adults age 21 or older and diagnosed with axial musculoskeletal back pain without radiculopathy.

  • Patients will be invited to participate if they own a smart phone (iPhone or Android device) and are able to download the pain app and the Quell Relief program app onto their device.

  • Patients will also be included if they:

    1. have chronic pain for > 3 months' duration
    2. average 4 or greater on a pain intensity scale of 0 to 10
    3. are able to speak and understand English.

Exclusion criteria

  • Patients will be excluded from participation if they meet any of the following criteria:

    1. diagnosis of cancer or any other malignant disease
    2. acute osteomyelitis or acute bone disease
    3. present or past Diagnostic and Statistical Manual-V diagnosis of schizophrenia, delusional disorder, psychotic disorder, or dissociative disorder that would be judged to interfere with study participation
    4. pregnancy
    5. any clinically unstable systemic illness judged to interfere with treatment
    6. a pain condition requiring urgent surgery
    7. an active substance use disorder, such as cocaine or IV heroin use, (positive on the Mini International Neuropsychiatric Interview; M.I.N.I. v.5.0) that would interfere with study participation
    8. any prescription opioid use for pain
    9. have an implanted cardiac pacemaker, defibrillator, or other implanted device. All subjects will be asked to not change their treatment during the study period.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

68 participants in 2 patient groups

Experimental
Experimental group
Description:
Subjects will receive the Quell device
Treatment:
Device: Quell
Control
No Intervention group
Description:
Subjects will not receive the Quell device

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems